



Clinical trial results:

A Phase II, open-label trial, to investigate pharmacokinetics, safety, tolerability and antiviral activity of TMC114/rtv b.i.d. in treatment-experienced HIV-1 infected children and adolescents - Analysis with cut-off date of 10 April 2008, at which time all subjects had reached Week 48 or discontinued before

Due to a system error, the data reported in v1 is not correct and has been removed from public view.

Summary

EudraCT number	2005-006179-11
Trial protocol	GB ES IT Outside EU/EEA
Global end of trial date	

Results information

Result version number	v2 (current)
This version publication date	23 June 2016
First version publication date	03 August 2015
Version creation reason	

Trial information

Trial identification

Sponsor protocol code	TMC114-C212
-----------------------	-------------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT00355524
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	Tibotec Pharmaceuticals
Sponsor organisation address	Eastgate Village, Eastgate,, Little Island, Co Cork, Ireland,
Public contact	Clinical Registry Group, Tibotec Pharmaceuticals, ClinicalTrialsEU@its.jnj.com
Scientific contact	Clinical Registry Group, Tibotec Pharmaceuticals, ClinicalTrialsEU@its.jnj.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	Yes
EMA paediatric investigation plan number(s)	EMA-000038-PIP01-07
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	Yes

Notes:

Results analysis stage

Analysis stage	Interim
Date of interim/final analysis	10 April 2008
Is this the analysis of the primary completion data?	No
Global end of trial reached?	No

Notes:

General information about the trial

Main objective of the trial:

The purpose of this study was to evaluate long-term safety, tolerability and efficacy of darunavir (DRV) in combination with low-dose ritonavir administered twice daily (b.i.d) and other antiretroviral (ARV) agents over a 24-week treatment period at the selected pediatric (greater than or equal to [\geq] 20 kilogram [kg] to less than [$<$] 50 kg) and adult (\geq 50 kg) doses.

Protection of trial subjects:

The safety assessments included clinical laboratory tests (hematology, coagulation, biochemistry, hepatitis serology/viremia and urinalysis), cardiovascular safety, vital signs, physical examination, electrocardiogram (ECG). Adverse events and vital signs were monitored throughout the study.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	13 July 2006
Long term follow-up planned	Yes
Long term follow-up rationale	Safety
Long term follow-up duration	12 Months
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Brazil: 10
Country: Number of subjects enrolled	Argentina: 17
Country: Number of subjects enrolled	Canada: 3
Country: Number of subjects enrolled	Spain: 5
Country: Number of subjects enrolled	France: 4
Country: Number of subjects enrolled	Italy: 3
Country: Number of subjects enrolled	Romania: 15
Country: Number of subjects enrolled	United States: 18
Country: Number of subjects enrolled	South Africa: 5
Worldwide total number of subjects	80
EEA total number of subjects	27

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	24
Adolescents (12-17 years)	56
Adults (18-64 years)	0
From 65 to 84 years	0
85 years and over	0

Subject disposition

Recruitment

Recruitment details: -

Pre-assignment

Screening details:

In total, 96 participants were screened (52 in Part 1 and 44 in Part 2). Of these 96 participants, 80 participants were treated, and 16 were screening failures.

Period 1

Period 1 title	Part 2 (overall period)
Is this the baseline period?	Yes
Allocation method	Non-randomised - controlled
Blinding used	Not blinded

Arms

Arm title	Darunavir plus Ritonavir
-----------	--------------------------

Arm description:

Participants administered with Darunavir 600 milligram (mg) in combination with low dose ritonavir 100 mg twice daily along with other antiretroviral (ARV) agents.

Arm type	Experimental
Investigational medicinal product name	TMC114 ethanolate
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Film-coated tablet
Routes of administration	Oral use

Dosage and administration details:

Participants administered with Darunavir 300 mg twice daily along with other ARV agents.

Investigational medicinal product name	TMC114 ethanolate
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Film-coated tablet
Routes of administration	Oral use

Dosage and administration details:

Participants administered with Darunavir 75 mg twice daily along with other ARV agents.

Investigational medicinal product name	Norvir
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Capsule, soft
Routes of administration	Oral use

Dosage and administration details:

Participants administered with Ritonavir 100 mg twice daily along with other ARV agents.

Investigational medicinal product name	Norvir
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Oral solution
Routes of administration	Oral use

Dosage and administration details:

Participants administered with Ritonavir 80 milligram(s)/millilitre (mg/ml) administered twice daily along with other ARV agents.

Number of subjects in period 1	Darunavir plus Ritonavir
Started	80
Completed	70
Not completed	10
Adverse event, serious fatal	1
Other	1
Unspecified	5
Subject noncompliant	3

Baseline characteristics

Reporting groups

Reporting group title	Darunavir plus Ritonavir
-----------------------	--------------------------

Reporting group description:

Participants administered with Darunavir 600 milligram (mg) in combination with low dose ritonavir 100 mg twice daily along with other antiretroviral (ARV) agents.

Reporting group values	Darunavir plus Ritonavir	Total	
Number of subjects	80	80	
Title for AgeCategorical Units: subjects			
Children (2-11 years)	24	24	
Adolescents (12-17 years)	56	56	
Title for AgeContinuous Units: years			
arithmetic mean	13.1		
standard deviation	± 3.11	-	
Title for Gender Units: subjects			
Female	23	23	
Male	57	57	

End points

End points reporting groups

Reporting group title	Darunavir plus Ritonavir
-----------------------	--------------------------

Reporting group description:

Participants administered with Darunavir 600 milligram (mg) in combination with low dose ritonavir 100 mg twice daily along with other antiretroviral (ARV) agents.

Subject analysis set title	PART-I: GROUP A
----------------------------	-----------------

Subject analysis set type	Sub-group analysis
---------------------------	--------------------

Subject analysis set description:

Participants administered with low doses of Darunavir in combination with Ritonavir (DRV) twice daily along with other antiretroviral (ARV) agents.

Subject analysis set title	PART-I: GROUP B
----------------------------	-----------------

Subject analysis set type	Sub-group analysis
---------------------------	--------------------

Subject analysis set description:

Participants administered with 20 to 33% higher dose of Darunavir in combination with Ritonavir (DRV) twice daily along with other antiretroviral (ARV) agents.

Primary: Percentage of Participants With Confirmed Virologic Response

End point title	Percentage of Participants With Confirmed Virologic Response ^[1]
-----------------	---

End point description:

Virologic response defined as the percentage of participants with a confirmed decrease of at least 1 log₁₀ from baseline in plasma viral load at Week 24 calculated according to the Food and Drug Administration (FDA) time to loss of virologic response (TLOVR) algorithm.

End point type	Primary
----------------	---------

End point timeframe:

Week 2, 4, 8, 12, 16, 20, 24, 32, 40 and 48

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Descriptive statistics were done, no inferential statistical analyses were performed.

End point values	Darunavir plus Ritonavir			
Subject group type	Reporting group			
Number of subjects analysed	80			
Units: Percentage of participants				
number (not applicable)				
Week 2	78.8			
Week 4	82.5			
Week 8	82.5			
Week 12	81.3			
Week 16	77.5			
Week 20	76.3			
Week 24	73.8			
Week 32	67.5			
Week 40	66.3			
Week 48	65			

Statistical analyses

No statistical analyses for this end point

Primary: Percentage of Participants With Observed Virologic Response Rate (at Least 0.5 log₁₀ Decrease) at Week 2

End point title	Percentage of Participants With Observed Virologic Response Rate (at Least 0.5 log ₁₀ Decrease) at Week 2 ^[2]
-----------------	---

End point description:

Participants observed with response at Week 2 defined as a drop in viral load (copies/mL) of at least 0.5 log₁₀ versus baseline.

End point type	Primary
----------------	---------

End point timeframe:

At week 2

Notes:

[2] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Descriptive statistics were done, no inferential statistical analyses were performed.

End point values	PART-I: GROUP A	PART-I: GROUP B		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	22	20		
Units: Percentage of participants				
number (not applicable)	90.9	100		

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Participants With Virologic Response

End point title	Percentage of Participants With Virologic Response
-----------------	--

End point description:

Virologic response defined as the percentage of participants with confirmed virologic response (viral load less than [$<$] 400 copies/milliliter [mL], TLOVR or viral load $<$ 50 copies/mL)

End point type	Secondary
----------------	-----------

End point timeframe:

Week 2, 4,8, 12,16, 20, 24, 32, 40 and 48

End point values	Darunavir plus Ritonavir			
Subject group type	Reporting group			
Number of subjects analysed	80			
Units: Percentage of participants				
number (not applicable)				
Week 2: Viral Load < 50 Copies/mL	5			
Week 4: Viral Load < 50 Copies/mL	11.3			
Week 8: Viral Load < 50 Copies/mL	26.3			
Week 12: Viral Load < 50 Copies/mL	36.3			
Week 16: Viral Load < 50 Copies/mL	46.3			
Week 20: Viral Load < 50 Copies/mL	52.5			
Week 24: Viral Load < 50 Copies/mL	50			
Week 32: Viral Load < 50 Copies/mL	50			
Week 40: Viral Load < 50 Copies/mL	48.8			
Week 48: Viral Load < 50 Copies/mL	47.5			
Week 2: Viral Load < 400 Copies/mL	33.8			
Week 4: Viral Load < 400 Copies/mL	50			
Week 8: Viral Load < 400 Copies/mL	56.3			
Week 12: Viral Load < 400 Copies/mL	65			
Week 16: Viral Load < 400 Copies/mL	66.3			
Week 20: Viral Load < 400 Copies/mL	66.3			
Week 24: Viral Load < 400 Copies/mL	65			
Week 32: Viral Load < 400 Copies/mL	62.5			
Week 40: Viral Load < 400 Copies/mL	60			
Week 48: Viral Load < 400 Copies/mL	58.8			

Statistical analyses

No statistical analyses for this end point

Secondary: Durability of Response

End point title	Durability of Response
-----------------	------------------------

End point description:

Durability of Response is defined as proportion of participants with at least 1 log₁₀ decrease in viral load or a viral load less than (<) 50 copies/milliliter (mL) at Week 48 versus Week 24. Here 'n' signifies the number of participants analysed at this time point.

End point type	Secondary
----------------	-----------

End point timeframe:

Week 24 and week 48

End point values	Darunavir plus Ritonavir			
Subject group type	Reporting group			
Number of subjects analysed	80			
Units: Percentage of participants				
number (not applicable)				
At least 1 log10 decrease from Baseline (n= 59)	88.1			
VL < 50 copies/mL (n= 40)	87.5			

Statistical analyses

No statistical analyses for this end point

Secondary: Change From Baseline in Log10 Viral Load

End point title	Change From Baseline in Log10 Viral Load
End point description: The change in plasma log10 viral load from baseline was calculated using the (NC = F) algorithm where non-completers are considered as failures after treatment discontinuation.	
End point type	Secondary
End point timeframe: Baseline, Week 2, 4,8, 12,16, 20, 24, 32, 40 and 48	

End point values	Darunavir plus Ritonavir			
Subject group type	Reporting group			
Number of subjects analysed	80			
Units: Copies/milliliter (mL)				
arithmetic mean (standard error)				
Baseline	4.64 (± 0.089)			
Change at Week 2	-1.63 (± 0.08)			
Change at Week 4	-1.83 (± 0.094)			
Change at Week 8	-1.88 (± 0.121)			
Change at Week 12	-2.04 (± 0.122)			
Change at Week 16	-1.99 (± 0.135)			
Change at Week 20	-1.96 (± 0.138)			
Change at Week 24	-1.98 (± 0.137)			
Change at Week 32	-1.83 (± 0.147)			
Change at Week 40	-1.8 (± 0.15)			
Change at Week 48	-1.81 (± 0.151)			

Statistical analyses

No statistical analyses for this end point

Secondary: Change From Baseline in Cluster of Differentiation 4 (CD4+) Cell Count

End point title	Change From Baseline in Cluster of Differentiation 4 (CD4+) Cell Count
-----------------	--

End point description:

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, Week 2, 4,8, 12,16, 20, 24, 32, 40 and 48

End point values	Darunavir plus Ritonavir			
Subject group type	Reporting group			
Number of subjects analysed	80			
Units: 10 ⁶ /liter (L)				
arithmetic mean (standard error)				
Baseline	390 (± 36.8)			
Week 2	35 (± 13.7)			
Week 4	70 (± 14.4)			
Week 8	69 (± 13.1)			
Week 12	116 (± 17.7)			
Week 16	69 (± 22.1)			
Week 20	97 (± 16.8)			
Week 24	117 (± 16.8)			
Week 32	108 (± 19.2)			
Week 40	148 (± 27.3)			
Week 48	147 (± 27.2)			

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

Up to Week 48

Assessment type	Non-systematic
-----------------	----------------

Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	9.1
--------------------	-----

Reporting groups

Reporting group title	Darunavir plus Ritonavir
-----------------------	--------------------------

Reporting group description:

Darunavir 600 milligram (mg) in combination with low dose ritonavir 100 mg administered twice daily and other antiretroviral (ARV) agents.

Serious adverse events	Darunavir plus Ritonavir		
Total subjects affected by serious adverse events			
subjects affected / exposed	20 / 80 (25.00%)		
number of deaths (all causes)	1		
number of deaths resulting from adverse events			
Investigations			
Alanine Aminotransferase Increased			
subjects affected / exposed	1 / 80 (1.25%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Blood Alkaline Phosphatase Increased			
subjects affected / exposed	1 / 80 (1.25%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Blood Amylase Increased			
subjects affected / exposed	1 / 80 (1.25%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Blood Albumin Decreased			
subjects affected / exposed	1 / 80 (1.25%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		

Nervous system disorders Partial Seizures	subjects affected / exposed	1 / 80 (1.25%)		
	occurrences causally related to treatment / all	0 / 1		
	deaths causally related to treatment / all	0 / 0		
General disorders and administration site conditions Pyrexia	subjects affected / exposed	1 / 80 (1.25%)		
	occurrences causally related to treatment / all	0 / 1		
	deaths causally related to treatment / all	0 / 0		
Blood and lymphatic system disorders Febrile Neutropenia	subjects affected / exposed	1 / 80 (1.25%)		
	occurrences causally related to treatment / all	0 / 1		
	deaths causally related to treatment / all	0 / 0		
Gastrointestinal disorders	Gastrointestinal Disorder			
	alternative assessment type: Systematic			
	subjects affected / exposed	1 / 80 (1.25%)		
	occurrences causally related to treatment / all	0 / 1		
	deaths causally related to treatment / all	0 / 0		
	Gastrointestinal Fistula			
	subjects affected / exposed	1 / 80 (1.25%)		
	occurrences causally related to treatment / all	0 / 1		
	deaths causally related to treatment / all	0 / 0		
	Diarrhoea			
	subjects affected / exposed	1 / 80 (1.25%)		
	occurrences causally related to treatment / all	0 / 1		
	deaths causally related to treatment / all	0 / 0		
Respiratory, thoracic and mediastinal disorders Rales	subjects affected / exposed	1 / 80 (1.25%)		
	occurrences causally related to treatment / all	0 / 1		
	deaths causally related to treatment / all	0 / 0		

Skin and subcutaneous tissue disorders			
Ecchymosis			
subjects affected / exposed	1 / 80 (1.25%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Rash Maculo-Papular			
subjects affected / exposed	1 / 80 (1.25%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Petechiae			
subjects affected / exposed	1 / 80 (1.25%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Musculoskeletal and connective tissue disorders			
Arthritis			
subjects affected / exposed	1 / 80 (1.25%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Neck Pain			
subjects affected / exposed	1 / 80 (1.25%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Osteochondrosis			
subjects affected / exposed	1 / 80 (1.25%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Infections and infestations			
Cellulitis			
subjects affected / exposed	1 / 80 (1.25%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Hepatitis A			

subjects affected / exposed	1 / 80 (1.25%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Mastoiditis				
subjects affected / exposed	1 / 80 (1.25%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Osteomyelitis Chronic				
subjects affected / exposed	1 / 80 (1.25%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Lobar Pneumonia				
subjects affected / exposed	1 / 80 (1.25%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Pneumonia				
subjects affected / exposed	5 / 80 (6.25%)			
occurrences causally related to treatment / all	0 / 7			
deaths causally related to treatment / all	0 / 0			
Pyothorax				
subjects affected / exposed	1 / 80 (1.25%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Endocarditis Bacterial				
subjects affected / exposed	1 / 80 (1.25%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Isosporiasis				
subjects affected / exposed	1 / 80 (1.25%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Influenza				

subjects affected / exposed	1 / 80 (1.25%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Herpes Zoster Disseminated			
subjects affected / exposed	1 / 80 (1.25%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Pneumonia Bacterial			
subjects affected / exposed	1 / 80 (1.25%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
Septic Shock			
subjects affected / exposed	1 / 80 (1.25%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Urinary Tract Infection			
subjects affected / exposed	1 / 80 (1.25%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	Darunavir plus Ritonavir		
Total subjects affected by non-serious adverse events			
subjects affected / exposed	73 / 80 (91.25%)		
Investigations			
International Normalised Ratio Increased			
subjects affected / exposed	4 / 80 (5.00%)		
occurrences (all)	4		
Injury, poisoning and procedural complications			
Excoriation			
subjects affected / exposed	4 / 80 (5.00%)		
occurrences (all)	4		
Nervous system disorders			

Headache subjects affected / exposed occurrences (all)	10 / 80 (12.50%) 18		
Blood and lymphatic system disorders Lymphadenopathy subjects affected / exposed occurrences (all)	13 / 80 (16.25%) 28		
Neutropenia subjects affected / exposed occurrences (all)	8 / 80 (10.00%) 16		
General disorders and administration site conditions Injection Site Nodule subjects affected / exposed occurrences (all)	6 / 80 (7.50%) 8		
Pyrexia subjects affected / exposed occurrences (all)	22 / 80 (27.50%) 42		
Pain subjects affected / exposed occurrences (all)	5 / 80 (6.25%) 6		
Eye disorders Conjunctivitis subjects affected / exposed occurrences (all)	10 / 80 (12.50%) 11		
Gastrointestinal disorders Nausea subjects affected / exposed occurrences (all)	6 / 80 (7.50%) 6		
Diarrhoea subjects affected / exposed occurrences (all)	14 / 80 (17.50%) 20		
Abdominal Pain subjects affected / exposed occurrences (all)	10 / 80 (12.50%) 10		
Vomiting			

subjects affected / exposed occurrences (all)	16 / 80 (20.00%) 18		
Respiratory, thoracic and mediastinal disorders			
Cough			
subjects affected / exposed	18 / 80 (22.50%)		
occurrences (all)	35		
Asthma			
subjects affected / exposed	4 / 80 (5.00%)		
occurrences (all)	7		
Epistaxis			
subjects affected / exposed	7 / 80 (8.75%)		
occurrences (all)	12		
Bronchospasm			
subjects affected / exposed	7 / 80 (8.75%)		
occurrences (all)	12		
Pharyngolaryngeal Pain			
subjects affected / exposed	5 / 80 (6.25%)		
occurrences (all)	8		
Rhinorrhoea			
subjects affected / exposed	4 / 80 (5.00%)		
occurrences (all)	10		
Wheezing			
subjects affected / exposed	4 / 80 (5.00%)		
occurrences (all)	5		
Nasal Congestion			
subjects affected / exposed	4 / 80 (5.00%)		
occurrences (all)	6		
Skin and subcutaneous tissue disorders			
Rash			
subjects affected / exposed	6 / 80 (7.50%)		
occurrences (all)	7		
Acne			
subjects affected / exposed	8 / 80 (10.00%)		
occurrences (all)	11		
Musculoskeletal and connective tissue disorders			

Arthralgia			
subjects affected / exposed	4 / 80 (5.00%)		
occurrences (all)	6		
Infections and infestations			
Bronchitis			
subjects affected / exposed	8 / 80 (10.00%)		
occurrences (all)	10		
Ear Infection			
subjects affected / exposed	7 / 80 (8.75%)		
occurrences (all)	12		
Herpes Zoster			
subjects affected / exposed	4 / 80 (5.00%)		
occurrences (all)	4		
Herpes Simplex			
subjects affected / exposed	14 / 80 (17.50%)		
occurrences (all)	23		
Oral Candidiasis			
subjects affected / exposed	4 / 80 (5.00%)		
occurrences (all)	7		
Nasopharyngitis			
subjects affected / exposed	8 / 80 (10.00%)		
occurrences (all)	16		
Influenza			
subjects affected / exposed	4 / 80 (5.00%)		
occurrences (all)	6		
Impetigo			
subjects affected / exposed	7 / 80 (8.75%)		
occurrences (all)	8		
Rhinitis			
subjects affected / exposed	7 / 80 (8.75%)		
occurrences (all)	10		
Pharyngitis			
subjects affected / exposed	6 / 80 (7.50%)		
occurrences (all)	7		
Otitis Media			

subjects affected / exposed	8 / 80 (10.00%)		
occurrences (all)	9		
Pneumonia			
subjects affected / exposed	13 / 80 (16.25%)		
occurrences (all)	15		
Tracheobronchitis			
subjects affected / exposed	5 / 80 (6.25%)		
occurrences (all)	7		
Upper Respiratory Tract Infection			
subjects affected / exposed	21 / 80 (26.25%)		
occurrences (all)	42		
Sinusitis			
subjects affected / exposed	10 / 80 (12.50%)		
occurrences (all)	14		
Tonsillitis			
subjects affected / exposed	13 / 80 (16.25%)		
occurrences (all)	19		

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
18 April 2007	The overall reason for the amendment was to adapt extension of the TMC114-C212 trial after Week 48 for participants less than or equal to (\leq) 18 years at the moment of reaching the week 48 visit, who continue to benefit from treatment with darunavir (DRV)/ritonavir (rtv) and who are living in a region where DRV pediatric use is not yet part of the label.

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported